Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Shares Rise on Positive Down Syndrome Test Study Results

NEW YORK (GenomeWeb News) – Shares of Sequenom rose nearly 22 percent today after the firm announced this morning that a blinded study showed that its molecular test for Down syndrome correctly identified 100 percent of all Down syndrome samples without any false-positive outcomes.
The San Diego-based firm conducted the study on 200 clinical samples collected prospectively and retrospectively. The SEQureDx technology that underlies the test “shows promise for significant performance advantages over the current paradigms for prenatal screening,” said Sequenom in a statement. The test uses a maternal blood sample that can be drawn as early as the first trimester and identifies directly the extra Number 21 chromosome, which is a marker for Down syndrome.
The firm intends to continue development of the test throughout 2008 and then transfer the technology to lab partners. Sequenom also intends to conduct a multi-site validation study using several thousand samples in the fourth quarter of 2008 and launch its own Down syndrome test as a Laboratory developed Test in the US during the first half of 2009.
Shares of Sequenom closed up 21.8 percent at $9.33 in heavy trading on the Nasdaq on Wednesday.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.